




Clinical Evidence for CytoSorb® Therapy in Acute Respiratory Distress Syndrome (ARDS)

Name	Title	Aim	Number of patients	Type of study	Outcome
🔗 Tomescu et al., Int J Artif Organs 2023; 46(12):605-617	The potential role of extracorporeal cytokine removal with CytoSorb® as an adjuvant therapy in Acute Respiratory Distress Syndrome	Narrative review of the role of CytoSorb® in pts with acute respiratory distress syndrome (ARDS)	N/A	Review	The review supports the concept of CytoSorb® in patients with severe ARDS with improvement in lung function and oxygenation, attenuation of the inflammatory response as well as a positive effect on hemodynamic stabilization and metabolic parameters, while having a very good safety profile without major device-related adverse events being reported to date.
🔗 Szigetváry et al., Biomedicines 2023; 11(11):3068	Hemoadsorption as Adjuvant Therapy in Acute Respiratory Distress Syndrome (ARDS): A Systematic Review and Meta-Analysis	Systematic review of all published data reporting on the use of hemoadsorption (HA) in patients with acute respiratory distress syndrome (ARDS)	N/A	Review	The authors conclude that use of HA resulted in a significant improvement in oxygenation and a reduction in norepinephrine dose and C-Reactive Protein levels in patients treated with ARDS without any serious adverse events reported.
🔗 Hayanga et al., Crit Care; 27(1):243	Extracorporeal hemoadsorption in critically ill COVID-19 patients in VV ECMO: The CytoSorb® Therapy in COVID-19 (CTC) Registry	Final report from CTC Registry from 5 US centres in patients on veno-venous extracorporeal membrane oxygenation (vvECMO) and CytoSorb® for COVID-19 related acute respiratory distress syndrome (ARDS)	100	Registry	This multicentre registry is the largest systematically collected dataset looking at use of CytoSorb® in VV ECMO patients. Results confirm that the approach is easy-to-implement, safe, and associated with high survival rates (74% at 90 days compared to ELSO registry data 52%). Early start may improve outcomes by reducing organ support requirements and length of ICU stay.





Clinical Evidence for CytoSorb® Therapy in Acute Respiratory Distress Syndrome (ARDS)





Name	Title	Aim	Number of patients	Type of study	Outcome
Akil et al., J Clin Med 2022; 11(20):5990	Use of CytoSorb® Hemoadsorption in Patients on Veno-Venous ECMO Support for Severe Acute Respiratory Distress Syndrome: A Systematic Review	Systematic review of all published data reporting on the use of CytoSorb® in patients with acute respiratory distress syndrome (ARDS) and veno-venous extracorporeal membrane oxygenation (vvECMO)	N/A	Systematic Review	Despite low patient numbers, there was a trend towards effective inflammatory biomarker reduction, decreased vasopressor dosage and improved lung function. Exploratory analyses suggest that these clinical benefits may also translate into lower mortality. Early initiation of CytoSorb® in the ECMO circuit might offer a new approach to enhance lung rest and promote recovery in these difficult to treat patients.
Kogelmann et al., J Int Care Soc 2020; 21(2):183-190	Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: A case series	Included consecutive pts with sepsis shock and ARDS treated with CytoSorb®, continuous renal replacement therapy and veno-venous extracorporeal membrane oxygenation (vvECMO)	7	Case Series	Pts had a significant stabilization in hemodynamics, reduction in hyperlactatemia, significant improvement in lung function and ventilation invasiveness. Severity of illness and overall organ dysfunction showed a considerable improvement during the course of the combined treatment while observed mortality was only half as predicted by APACHE II.

CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany
T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

Register for the literature newsletter

Visit our literature database for an overview of all references





www.cytosorb.com

The clinical and preclinical data and results obtained with the CytoSorb® adsorber are not transferable to other products. CytoSorb® should only be administered by health care professionals, properly trained in administration of extracorporeal therapies. The statements here represent the personal opinions and views of the author(s) only and do not necessarily reflect accepted medical knowledge in general or indications covered by the intended use of CytoSorb®. CytoSorb® and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2023, CytoSorbents Europe GmbH. All rights reserved. B1381R01ENG2023